Work

DNA-based MRD monitoring enhances risk stratification during TKI dose reduction in CML: Evidence from the clinical trial

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-78

Authors: Katerina Machova Polakova, Hana Žižková, Romana Vajnerova, Pavla Suchankova, Adela Benesova, Tomas Hornak, Hana Klamova, Dana Srbova, Cyril Salek, Edgar Faber, Tomas Papajik, Petra Belohlavkova, Jaroslava Voglova, Pavel Zak, Lukas Stejskal, Olga Cerna, Eduard Cmunt, Ivana Jeziskova, Tomas Jurcek, Jiri Mayer, Daniela Zackova

Institutions: Institute of Haematology and Blood Transfusion, University Hospital Brno, University Hospital Olomouc, University Hospital Hradec Králové, University Hospital Ostrava, University Hospital Kralovske Vinohrady, General University Hospital in Prague

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7108478750

Cites:

Cited by:

Related to: